AI brief of an SEC Form 8-K · Hims & Hers Health (HIMS)

Hims & Hers Q2 revenue rises 73% to $544.8 million; full-year guidance affirmed

Mixed Impact 3 of 5 earnings Written later

Hims & Hers reported second-quarter 2025 revenue of $544.8 million, up 73% from a year earlier, and net income of $42.5 million, compared with $13.3 million in the second quarter of 2024. The company affirmed its full-year 2025 revenue and Adjusted EBITDA guidance and gave third-quarter outlook, but free cash flow was negative $69.4 million and gross margin fell to 76% from 81%.

Key points

  • Q2 2025 revenue was $544.8 million, up 73% from $315.6 million; subscribers reached 2,439 thousand, up 31%
  • Net income was $42.5 million and Adjusted EBITDA was $82.2 million, versus $13.3 million and $39.3 million a year earlier
  • Free cash flow was negative $69.4 million, compared with positive $47.6 million in Q2 2024
  • Full-year 2025 guidance affirmed: revenue of $2.3 billion to $2.4 billion and Adjusted EBITDA of $295 million to $335 million; Q3 revenue guidance is $570 million to $590 million

The filing

CompanyHims & Hers Health (HIMS)
Form8-K, current report
Filed with the SECAug 4, 2025, 4:13 PM ET
Accession number0001773751-25-000248

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.